Barclays lowered the firm’s price target on Surgery Partners (SGRY) to $18 from $24 and keeps an Equal Weight rating on the shares. The firm says employer-sponsored insurance coverage looks under pressure but will be “potentially masked” by positive Affordable Care Act trends benefiting hospitals.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $22 from $28 at Mizuho
- Surgery Partners price target lowered to $29 from $34 at UBS
- Surgery Partners Appoints New COO and President
- Strategic Growth and Portfolio Optimization Drive Buy Rating for Surgery Partners
- Surgery Partners price target lowered to $31 from $35 at RBC Capital